Patents Assigned to Cognate BioServices, Inc.
  • COMBINATIONS OF CHECKPOINT INHIBITORS AND THERAPEUTICS TO TREAT CANCER
    Publication number: 20240382572
    Abstract: The present disclosure arises at least in part from the seminal recognition that a combination treatment regimen including one or more cycles and/or doses of a checkpoint inhibitor and a therapeutic, either sequentially, in either order, or substantially simultaneously, can be more effective in treating cancer in some subjects and/or can initiate, enable, increase, enhance or prolong the activity and/or number of immune cells, or a medically beneficial response by a tumor.
    Type: Application
    Filed: March 25, 2024
    Publication date: November 21, 2024
    Applicants: Cognate Bioservices, Inc., Northwest Biotherapeutics, Inc., The Regents of the University of California, RevImmune, Inc.
    Inventors: Marnix Leo Bosch, James Kelly Ganjei, Linda F. Powers, Linda M. Liau, Robert M. Prins
  • COMBINATIONS OF CHECKPOINT INHIBITORS AND THERAPEUTICS TO TREAT CANCER
    Publication number: 20240358807
    Abstract: A combination treatment regimen including one or more cycles and/or doses of a checkpoint inhibitor and a therapeutic, either sequentially, in either order, or substantially simultaneously, can be more effective in treating cancer in some subjects and/or can initiate, enable, increase, enhance or prolong the activity and/or number of immune cells, the efficacy of anti-tumor immune responses or a medically beneficial response by a tumor.
    Type: Application
    Filed: October 18, 2023
    Publication date: October 31, 2024
    Applicants: Cognate Bioservices, Inc., Northwest Biotherapeutics, Inc., The Regents of the University of California, RevImmune, Inc.
    Inventors: Marnix Leo Bosch, James Kelly Ganjei, Linda F. Powers, Linda M. Liau, Robert M. Prins
  • Isolation and purification of hematopoietic stem cells from post-liposuction lipoaspirates
    Patent number: 9255249
    Abstract: The present invention relates to a method of isolating hematopoietic stem cells from adipose tissue. The method yields a notably high number of CD34+, ALDHbr and/or ABCG2-expressing cells, comprising hematopoietic stem cells, permitting the use of the cells with no or minimal expansion.
    Type: Grant
    Filed: January 8, 2007
    Date of Patent: February 9, 2016
    Assignee: Cognate BioServices, Inc.
    Inventor: James B. Mitchell, II
  • Use Of Umbilical Cord Matrix Cells
    Publication number: 20080299090
    Abstract: The invention relates to the isolation and use of stem cells from amniote species (potentially any animal with an umbilical cord, including humans). More particularly the invention relates to obtaining stem cells that are at least multipotent and may be totipotent or nearly totipotent and are envisaged to have a variety of end uses. The cells of the present invention are immunosuppressive and may be used to inhibit the immune response in a subject.
    Type: Application
    Filed: March 21, 2008
    Publication date: December 4, 2008
    Applicants: Kansas State University Research Foundation, Cognate BioServices, Inc.
    Inventors: Mark Weiss, Rita Weiss, Cameron Anderson, Satish Medicetty, Irene Vanderwerff, Kevin R. McIntosh